These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
338 related items for PubMed ID: 9669425
21. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clardy CW, Forristal J, Strife CF, West CD. Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424 [Abstract] [Full Text] [Related]
22. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G, Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy, Nastasi. J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465 [Abstract] [Full Text] [Related]
23. Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Braun MC, West CD, Strife CF. Am J Kidney Dis; 1999 Dec; 34(6):1022-32. PubMed ID: 10585311 [Abstract] [Full Text] [Related]
24. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Ohi H, Yasugi T. Clin Exp Immunol; 1994 Feb; 95(2):316-21. PubMed ID: 8306508 [Abstract] [Full Text] [Related]
25. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. Carrara C, Podestà MA, Abbate M, Rizzo P, Piras R, Alberti M, Daina E, Ruggenenti P, Remuzzi G, on behalf of the EAGLE Study Group. Nephron; 2020 Feb; 144(4):195-203. PubMed ID: 32050203 [Abstract] [Full Text] [Related]
26. In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Jansen JH, Høgåsen K, Harboe M, Hovig T. Kidney Int; 1998 Feb; 53(2):331-49. PubMed ID: 9461093 [Abstract] [Full Text] [Related]
27. Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis. Wyatt RJ, McAdams AJ, Forristal J, Snyder J, West CD. Kidney Int; 1979 Oct; 16(4):505-12. PubMed ID: 398417 [Abstract] [Full Text] [Related]
28. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V. Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601 [Abstract] [Full Text] [Related]
29. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, Cailliez M, Deschenes G, Fischbach M, Karras A, Nobili F, Pietrement C, Dragon-Durey MA, Fakhouri F, Roumenina LT, Fremeaux-Bacchi V. Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854 [Abstract] [Full Text] [Related]
30. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis. Hiramatsu M, Balow JE, Tsokos GC. J Immunol; 1986 Jun 15; 136(12):4451-5. PubMed ID: 3011894 [Abstract] [Full Text] [Related]
31. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ. Clin J Am Soc Nephrol; 2011 May 15; 6(5):1009-17. PubMed ID: 21415311 [Abstract] [Full Text] [Related]
32. Membranoproliferative glomerulonephritis with isolated C3 deposits: case report and literature review. Darouich S, Goucha R, Jaafoura MH, Zekri S, Kheder A, Ben Maiz H. Ultrastruct Pathol; 2011 Feb 15; 35(1):42-6. PubMed ID: 21265634 [Abstract] [Full Text] [Related]
33. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Leroy V, Fremeaux-Bacchi V, Peuchmaur M, Baudouin V, Deschênes G, Macher MA, Loirat C. Pediatr Nephrol; 2011 Mar 15; 26(3):419-24. PubMed ID: 21188423 [Abstract] [Full Text] [Related]
34. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M. Clin Exp Immunol; 1989 Apr 15; 76(1):82-5. PubMed ID: 2736802 [Abstract] [Full Text] [Related]
35. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis. Ohi H, Watanabe S, Fujita T, Seki M, Hatano M. J Immunol Methods; 1990 Jul 20; 131(1):71-6. PubMed ID: 2380570 [Abstract] [Full Text] [Related]
36. [Prominent subepithelial deposits detected on 2nd renal biopsy in a boy with membranoproliferative glomerulonephritis type I: a case report]. Motoyama O, Ohshima M, Kawamura S, Iitaka K. Nihon Jinzo Gakkai Shi; 1995 Apr 20; 37(4):247-52. PubMed ID: 7602812 [Abstract] [Full Text] [Related]
40. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G, EAGLE Study Group. Am J Kidney Dis; 2019 Aug 20; 74(2):224-238. PubMed ID: 30929851 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]